Vaccine

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology   Paris,…

2 years ago

BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa,…

2 years ago

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated…

2 years ago

CytoDyn to Host Webcast to Provide Company Update

VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

2 years ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio…

2 years ago

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted…

2 years ago

NanoViricides Bolsters Partnership Efforts – Engages Aagami Inc.

SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in…

2 years ago

IO Biotech to Present at Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…

2 years ago

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical…

2 years ago